Tremfya Insurance Denial Appeal Guide

Tremfya (guselkumab) is an IL-23 inhibitor for moderate-to-severe plaque psoriasis and psoriatic arthritis. Step therapy through TNF inhibitors is the primary barrier to coverage.

Why Tremfya Gets Denied

IL-23 inhibitors like Tremfya are considered advanced biologics. Insurers require failure of TNF inhibitors and sometimes IL-17 inhibitors before approving IL-23 therapy. Formulary preference between Tremfya and Skyrizi is also common.

Common Denial Reasons

  • Step therapy not met (TNF and/or IL-17 failure required)
  • Preferred IL-23 inhibitor on formulary (Skyrizi)
  • BSA or PASI documentation insufficient
  • Prior authorization expired
  • Non-covered indication

Appeal Strategy

  1. Document all prior biologic failures with specific dates and outcomes
  2. Show persistent moderate-to-severe disease — PASI ≥12, BSA ≥10%
  3. Reference IL-23 class advantages — longer dosing intervals (every 8 weeks), durable response
  4. If Skyrizi is preferred — explain clinical differentiation or document Skyrizi failure
  5. Cite VOYAGE trial data showing superiority over Humira

Dosing Advantage

Tremfya's every-8-weeks maintenance dosing (after loading) is less frequent than many biologics. This improves compliance and can support appeals based on patient adherence history.

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

What is the difference between Tremfya and Skyrizi?

Both target IL-23 but bind different subunits (p19). They have similar efficacy profiles. Choice is often based on formulary coverage, dosing preference, and individual patient response.

How effective is Tremfya for psoriasis?

In clinical trials, approximately 73-80% of patients achieved PASI 90 (90% improvement) at week 48. This is significantly higher than TNF inhibitor response rates.

Related Resources